--- title: "Nomura expects WuXi AppTec's revenue this year to exceed market expectations, raising the target price to 157.07 yuan" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/275694444.md" description: "Nomura expects WuXi AppTec's revenue in Q4 2025 to grow by 9.2% to RMB 11.7 billion, with net profit increasing by 142% to RMB 7.1 billion. For the fiscal year 2026, revenue is projected to grow by 16% to RMB 52.6 billion, and profit is expected to increase by 3% to RMB 19.6 billion. Revenue from TIDES and later-stage development and manufacturing businesses is expected to grow by 55% and 10%, respectively. The target price has been raised from HKD 132.8 to HKD 157.07, and the A-share target price has been increased from RMB 120.85 to RMB 142.93, both with a \"Buy\" rating" datetime: "2026-02-12T03:21:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275694444.md) - [en](https://longbridge.com/en/news/275694444.md) - [zh-HK](https://longbridge.com/zh-HK/news/275694444.md) --- > 支持的语言: [English](https://longbridge.com/en/news/275694444.md) | [繁體中文](https://longbridge.com/zh-HK/news/275694444.md) # Nomura expects WuXi AppTec's revenue this year to exceed market expectations, raising the target price to 157.07 yuan Nomura's research report indicates that based on WuXi AppTec (02359.HK) announcing a positive profit forecast, it is expected that revenue in the fourth quarter of 2025 will grow by 9.2% year-on-year to RMB 11.7 billion, with net profit increasing by 142% to RMB 7.1 billion. Looking ahead to the fiscal year 2026, the company’s revenue is expected to grow by 16% year-on-year to RMB 52.6 billion, exceeding market expectations of RMB 51.1 billion, due to strong performance in the chemical business; profit is expected to grow by 3% year-on-year to RMB 19.6 billion. The year-on-year growth rate for continuing operations is 21%. By business segment, the bank expects that in fiscal year 2026, revenue from TIDES and late-stage development and manufacturing will grow by 55% and 10% year-on-year, reaching RMB 17.1 billion and RMB 21.6 billion, respectively. The growth in TIDES business is based on sustained demand and supported by the company's 100,000-liter large-scale functional production capacity. The bank has raised the target price for WuXi AppTec's H shares from HKD 132.8 to HKD 157.07, and the target price for WuXi AppTec's A shares (603259.SH) from RMB 120.85 to RMB 142.93, both with a "Buy" rating ### 相关股票 - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-CN/quote/159892.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-CN/quote/520690.CN.md) - [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/zh-CN/quote/520500.CN.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-CN/quote/513700.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-CN/quote/159849.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-CN/quote/510660.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md) - [WuXi AppTec (603259.CN)](https://longbridge.com/zh-CN/quote/603259.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-CN/quote/513120.CN.md) - [WUXI APPTEC (02359.HK)](https://longbridge.com/zh-CN/quote/02359.HK.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-CN/quote/159316.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-CN/quote/159992.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-CN/quote/520880.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-CN/quote/588130.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-CN/quote/159506.CN.md) - [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/zh-CN/quote/159570.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-CN/quote/512290.CN.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-CN/quote/513060.CN.md) ## 相关资讯与研究 - [Jacobio Pharma: Differentiated Pan-KRAS Profile, Multiple Clinical Catalysts, and Solid Balance Sheet Underscore Buy Rating](https://longbridge.com/zh-CN/news/278909908.md) - [Fosun Pharma Unit Gets China Nod for Hematological Malignancy Drug Trial](https://longbridge.com/zh-CN/news/279052280.md) - [China Medical System Gets China Nod to Market Renal Anaemia Drug](https://longbridge.com/zh-CN/news/279046722.md) - [Kintor Partners With Fonow Medicine to Commercialize KT-939 Functional Cosmetics in China](https://longbridge.com/zh-CN/news/278891486.md) - [SSY Gets China Nod for Production, Registration of Vitamin Injection](https://longbridge.com/zh-CN/news/279036594.md)